TJ101 is a bispecific antibody-drug conjugate (ADC) targeting EGFR and B7-H3, currently in phase 1 clinical trial for the treatment of advanced solid tumors. TJ101 leverages bispecific ADC technology to enhance tumor selectivity and minimize off-tumor toxicity, compared to traditional monoclonal ADCs.

EGFR is a clinically validated oncology target that drives tumor growth and metastasis, whereas B7-H3 is an immune checkpoint protein associated with tumor progression and has highly limited normal tissue expression. EGFR and B7-H3 are frequently co-expressed in solid tumors, including lung cancer and head and neck cancer, making them ideal bispecific ADC targets.

TJ101 consists of a humanized IgG1 bispecific antibody synthesized using KIH technology, conjugated to a proprietary topoisomerase I inhibitor, PY-4CAR2, via a cleavable linker at a DAR of 8. Upon tumor cell internalization, the linker is enzymatically cleaved in lysosomes, releasing the payload for direct tumor cell killing and potent bystander killing of neighboring tumor cells. Preclinical studies confirm that TJ101 selectively binds EGFR/B7-H3 co-expressing tumors, induces potent cell killing, and demonstrates strong anti-tumor efficacy in mouse models.

TJ102 is a bispecific, dual-payload ADC targeting FRα and CDH6. It conjugates both a topoisomerase I inhibitor and a microtubule inhibitor as cytotoxic payloads. The program is currently in IND-enabling studies.

TTJ106 is a biparatopic, dual-payload ADC that targets two extracellular domains of HER2 and is conjugated with both a topoisomerase I inhibitor and a microtubule inhibitor. It is currently in preclinical development.

TJ108 is a bispecific, dual-payload ADC targeting EGFR and cMET. It conjugates both a topoisomerase I inhibitor and a microtubule inhibitor as cytotoxic payloads. The program is currently in preclinical development.

TJ109 is a bispecific, dual-payload ADC targeting EGFR and HER3. It conjugates both a topoisomerase I inhibitor and a microtubule inhibitor as cytotoxic payloads. The program is currently in preclinical development.

TJ111 is a bispecific, dual-payload ADC targeting Trop2 and Nectin4. It conjugates both a topoisomerase I inhibitor and a microtubule inhibitor as cytotoxic payloads. The program is currently in preclinical development.

TJ101 is a bispecific antibody-drug conjugate (ADC) targeting EGFR and B7-H3, currently in phase 1 clinical trial for the treatment of advanced solid tumors. TJ101 leverages bispecific ADC technology to enhance tumor selectivity and minimize off-tumor toxicity, compared to traditional monoclonal ADCs.

EGFR is a clinically validated oncology target that drives tumor growth and metastasis, whereas B7-H3 is an immune checkpoint protein associated with tumor progression and has highly limited normal tissue expression. EGFR and B7-H3 are frequently co-expressed in solid tumors, including lung cancer and head and neck cancer, making them ideal bispecific ADC targets.

TJ101 consists of a humanized IgG1 bispecific antibody synthesized using KIH technology, conjugated to a proprietary topoisomerase I inhibitor, PY-4CAR2, via a cleavable linker at a DAR of 8. Upon tumor cell internalization, the linker is enzymatically cleaved in lysosomes, releasing the payload for direct tumor cell killing and potent bystander killing of neighboring tumor cells. Preclinical studies confirm that TJ101 selectively binds EGFR/B7-H3 co-expressing tumors, induces potent cell killing, and demonstrates strong anti-tumor efficacy in mouse models.

TJ102 is a bispecific, dual-payload ADC targeting FRα and CDH6. It conjugates both a topoisomerase I inhibitor and a microtubule inhibitor as cytotoxic payloads. The program is currently in IND-enabling studies.

TTJ106 is a biparatopic, dual-payload ADC that targets two extracellular domains of HER2 and is conjugated with both a topoisomerase I inhibitor and a microtubule inhibitor. It is currently in preclinical development.

TJ108 is a bispecific, dual-payload ADC targeting EGFR and cMET. It conjugates both a topoisomerase I inhibitor and a microtubule inhibitor as cytotoxic payloads. The program is currently in preclinical development.

TJ109 is a bispecific, dual-payload ADC targeting EGFR and HER3. It conjugates both a topoisomerase I inhibitor and a microtubule inhibitor as cytotoxic payloads. The program is currently in preclinical development.

TJ111 is a bispecific, dual-payload ADC targeting Trop2 and Nectin4. It conjugates both a topoisomerase I inhibitor and a microtubule inhibitor as cytotoxic payloads. The program is currently in preclinical development.